Additional file 1 of Association of non-high-density lipoprotein cholesterol trajectories with the development of non-alcoholic fatty liver disease: an epidemiological and genome-wide association study
Creators: name: Lee, Jun-Hyuk
name: Kim, Jiyeon
name: Kim, Jung Oh
name: Kwon, Yu-Jin
Publisher: name: figshare
Year: 2024
Subjects: subject: Biochemistry
subject: Medicine
subject: Genetics
subject: FOS: Biological sciences
subject: Biotechnology
subject: Chemical Sciences not elsewhere classified
subject: Sociology
subject: FOS: Sociology
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Mathematical Sciences not elsewhere classified
subject: Developmental Biology

description: Additional file 1: Figure S1. Trajectory modeling with non-HDL cholesterol using the latent class linear mixed model. Red line: non-HDL cholesterol increasing group, blue line: non-HDL cholesterol stable group. HDL, high-density lipoprotein. Figure S2. Manhattan Plot of the NAFLD-control analysis based on liver fat score. The P values are represented in genomic order by chromosome and position on the chromosome (x-axis). The value on the y-axis represents the −log10 of the p-value (equivalent to the number of zeros after the decimal point plus one). The blue dotted line indicates p-values ≤ 1.0 x 10-5. There are no SNPs reaching p-values ≤ 1.0 x 10-8. NAFLD, non-alcoholic fatty liver disease; SNP, single nucleotide polymorphism. Figure S3. Quantile-quantile plot of the GWAS p-values for NAFLD. The x-axis and y-axis represent the expected p-values and the observed p-values, respectively. The red line indicates observed p-values are equal to expected p-values. GWAS, genome-wide association study; NAFLD, non-alcoholic fatty liver disease. Figure S4. Miami Plot of the NAFLD-control analysis stratified on the trajectory model, the increased group, and the stable group for cholesterol excluding HDL cholesterol. (A) Miami plot of the GWAS result. (B) Miami plot of the Model 2 GWAS result. (C) Miami plot of the Model 3 GWAS result. (D) Miami plot of the Model 4 GWAS result. Each Miami plot shows results for NAFLD status in stable group (blue) and the increasing group (red). The models differ in terms of the covariates used for the analysis. In Model 1, age and sex were included as confounding variables, PC1~10. In Model 2, age, sex, BMI, total energy intake, smoking status, drinking status, and physical activity variables were used. In Model 3, the variables used in Model 2 were included, in addition to which HTN, DM, and serum CRP level were adjusted. In Model 4, the serum ALT level was further adjusted from Model 3. NAFLD, non-alcoholic fatty liver disease; HDL, high-density lipoprotein; GWAS, genome-wide association study; BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; CRP, C-reactive protein; ALT, alanine aminotransferase. Figure S5. Manhattan plot of the increasing group vs. the stable group interaction GWAS results: (A) Model 1, (B) Model 2, (C) Model 3, and (D) Model 4. The models differ in the covariates used in the analysis. In Model 1, age and sex were included as confounding variables, PC1~10. In Model 2, age, sex, BMI, total energy intake, smoking status, drinking status, physical activity variables were used. In Model 3, the variables used in Model 2 were included, in addition to which HTN, DM, and serum CRP level were adjusted. In Model 4, the serum ALT level was further adjusted from Model 3. GWAS, genome-wide association study; PC, principal component; BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; CRP, C-reactive protein; ALT, alanine aminotransferase.